

Grifols welcomes Egypt's ambassador to Spain at its plasma processing plant in Parets del Vallès

- *His Excellency Youssef Mekkawy toured the facility where plasma-derived medicines for Grifols Egypt are manufactured from Egyptian plasma until a new production site in Egypt is operational*
- *Grifols and the Egyptian government's National Service Projects Organization are making great strides in their joint-venture to ensure Egypt's self-sufficiency in plasma medicines*

Barcelona, Spain, June 14, 2023 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global leader in plasma medicines with more than 110 years contributing to improve the health and well-being of people, today announced that Egypt's ambassador to Spain, His Excellency Youssef Mekkawy, toured the Grifols plant in Parets del Vallès (Barcelona), where he took in the world-class engineering currently being applied to the new Grifols Egypt manufacturing site being built in his country.

During his institutional visit, his first to Grifols, he met with company executives including Thomas Glanzmann, Executive Chairman and CEO; Raimon Grifols, Chief Corporate Officer; Victor Grifols Deu, Chief Operating Officer, as well as Grifols board member Tomás Dagà. Present from Grifols Egypt were Dr. Magdy Amin, CEO; and Dr. Ahmed Serag, head of Strategy and Projects.

The ambassador reaffirmed his country's commitment to Grifols Egypt for Plasma Derivatives, a joint venture between Grifols and Egypt's National Services Projects Organization to develop a fully integrated plasma-supply infrastructure that ensures domestic and regional self-sufficiency in plasma-derived medicines.

On his tour of the Parets del Vallès plant, he singled out the advanced automation of the operations and strict adherence to the highest international levels of quality and safety, characteristics that will also define the new Grifols Egypt manufacturing facilities under construction in the New Administrative Capital's medical city. Once completed at the end of 2025 and operational, the site will produce the Grifols Egypt plasma-derived products that Parets del Vallès is manufacturing in the meantime. Last week Grifols Egypt announced it is about to deliver its first shipment of medicines – albumin – to local hospitals.

All plasma for Grifols Egypt treatments comes from Egyptian donors and a growing network of plasma centers in the country. Six are open, another four are expected to be running before year-end, and in 2024 a total of 20 centers will be accepting donations.

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Tel. +34 93 571 00 02

Spain

Duomo Communication

Tel.: +34 91 311 92 89 – 91 311 92 90

Raquel Lumbreras

raquel_lumbreras@duomocomunicacion.com

Tel.: +34 659 57 21 85

Borja Gómez

borja_gomez@duomocomunicacion.com

Tel.: 650 40 22 25

Investor contact:

Investor Relations

inversores@grifols.com - investors@grifols.com

Tel.: +34 93 571 02 21

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and our ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 400 across North America, Europe, Africa and the Middle East and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. We provide high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

In 2022, Grifols' economic impact in its core countries of operation was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.